<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Transplant Direct</journal-id><journal-id journal-id-type="iso-abbrev">Transplant Direct</journal-id><journal-id journal-id-type="pmc-domain-id">2975</journal-id><journal-id journal-id-type="pmc-domain">transdir</journal-id><journal-id journal-id-type="publisher-id">TXD</journal-id><journal-title-group><journal-title>Transplantation Direct</journal-title></journal-title-group><issn pub-type="epub">2373-8731</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10065838</article-id><article-id pub-id-type="pmcid-ver">PMC10065838.1</article-id><article-id pub-id-type="pmcaid">10065838</article-id><article-id pub-id-type="pmcaiid">10065838</article-id><article-id pub-id-type="pmid">37009168</article-id><article-id pub-id-type="doi">10.1097/TXD.0000000000001439</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>016</subject></subj-group><subj-group subj-group-type="heading"><subject>Kidney Transplantation</subject></subj-group></article-categories><title-group><article-title>Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Haverals</surname><given-names initials="L">Lien</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roosens</surname><given-names initials="L">Laurence</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wouters</surname><given-names initials="K">Kristien</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marquet</surname><given-names initials="P">Pierre</given-names></name><degrees>MD, PhD</degrees><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Monchaud</surname><given-names initials="C">Caroline</given-names></name><degrees>MD, PhD</degrees><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Massart</surname><given-names initials="A">Annick</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abramowicz</surname><given-names initials="D">Daniel</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hellemans</surname><given-names initials="R">Rachel</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><aff id="aff1"><label>1</label> Department of Nephrology, Antwerp University Hospital, Edegem, Belgium.</aff><aff id="aff2"><label>2</label> Department of Clinical and Biological Sciences, Antwerp University Hospital, Edegem, Belgium.</aff><aff id="aff3"><label>3</label> Department of Statistics, Antwerp University Hospital, Edegem, Belgium.</aff><aff id="aff4"><label>4</label> Department of Pharmacology and Transplantation, University of Limoges, CHU Limoges, Limoges, France.</aff><aff id="aff5"><label>5</label> Laboratory of Experimental Medicine and Pediatrics and Member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium.</aff></contrib-group><author-notes><corresp id="c1">Correspondence: Rachel Hellemans, MD, PhD, Department of Nephrology, Faculty of Medicine and Health Sciences, Antwerp University Hospital and University of Antwerp, Drie Eikenstraat 655, 2650 Edegem, Belgium (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="rachel.hellemans@uza.be">rachel.hellemans@uza.be</email>) or Lien Haverals, MD, Department of Nephrology, Faculty of Medicine and Health Sciences, Antwerp University Hospital and University of Antwerp, Drie Eikenstraat 655, 2650 Edegem, Belgium (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="lienhaverals@hotmail.com">lienhaverals@hotmail.com</email>).</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>9</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">431441</issue-id><elocation-id>e1439</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2022</year></date><date date-type="rev-recd"><day>8</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>01</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-03 12:10:11.213"><day>03</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="txd-9-e1439.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="txd-9-e1439.pdf"/><abstract><title>Background.</title><p>Tacrolimus (Tac) has a narrow therapeutic range. Dosing is generally targeted at Tac trough levels (<italic toggle="yes">C</italic><sub>0</sub>), notwithstanding conflicting reports on the correlation between Tac <italic toggle="yes">C</italic><sub>0</sub> and systemic exposure measured by the area-under-the-concentration-over-time curve (AUC). The Tac dose required to meet the target <italic toggle="yes">C</italic><sub>0</sub> varies highly among patients. We hypothesized that patients requiring a relatively high Tac dose for a certain <italic toggle="yes">C</italic><sub>0</sub> may show a higher AUC.</p><sec><title>Methods.</title><p>We retrospectively analyzed data from 53 patients in which a 24-h Tac AUC<sub>24</sub> estimation was performed at our center. Patients were divided into those taking a low (&#8804;0.15&#8201;mg/kg) or high (&gt;0.15&#8201;mg/kg) once-daily Tac dose. Multiple linear regression models were used to investigate if the association between <italic toggle="yes">C</italic><sub>0</sub> and AUC<sub>24</sub> changes according to dose level.</p></sec><sec><title>Results.</title><p>Despite the large difference in mean Tac dose between the low- and high-dose group (7 versus 17&#8201;mg/d), <italic toggle="yes">C</italic><sub>0</sub> levels were similar. However, the mean AUC<sub>24</sub> was substantially higher in the high-dose group (320&#8201;&#177;&#8201;96 h&#183;&#956;g/L versus 255&#8201;&#177;&#8201;81 h&#183;&#956;g/L, <italic toggle="yes">P</italic> &lt; 0.001). This difference remained significant after adjusting for age and race. For a same <italic toggle="yes">C</italic><sub>0</sub>, every 0.01&#8201;mg/kg increase in Tac dose resulted in an AUC<sub>24</sub> increase of 3.59 h&#183;&#956;g/L.</p></sec><sec><title>Conclusions.</title><p>This study challenges the general belief that <italic toggle="yes">C</italic><sub>0</sub> levels are sufficiently reliable to estimate systemic drug exposure. We demonstrated that patients requiring a relatively high Tac dose to attain therapeutic <italic toggle="yes">C</italic><sub>0</sub> levels have higher drug exposure and could therefore potentially be overdosed.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The calcineurin-inhibitor tacrolimus (Tac) is a central component of the antirejection therapy of most solid organ transplant recipients.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> It is marketed as immediate-release Tac tablets for twice-daily administration or as modified-release tablets for once-daily administration (TacQD). TacQD shows the same efficacy as Tac tablets for twice-daily administration in terms of renal function, patient and graft survival at 12 mo, and a similar safety profile.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup></p><p>Tac is extensively metabolized by intestinal and hepatic cytochrome P450 3A (CYP3A5 and CYP3A4) and effluxed by P-glycoprotein expressed in the intestinal mucosa.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup> These presystemic processes contribute significantly to large variability in the rate and extent of drug absorption.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> Tac oral bioavailability is the result of the gastrointestinal transit time influenced by the presence or absence of food, efflux transport, and intestinal and hepatic first-pass.</p><p>In addition, the relative clearance of Tac is affected by various clinical parameters, such as age, sex, body size measures, race, time on Tac, serum albumin, hematocrit, and the presence of hepatitis B or C infection or other liver diseases.<sup><xref rid="R7" ref-type="bibr">7</xref></sup></p><p>Patients with a systemic Tac exposure below the target range may be at an increased risk of developing acute or chronic rejection because of insufficient immunosuppression, whereas high systemic Tac exposure increases the risk of adverse effects, such as nephrotoxicity, neurotoxicity, and posttransplant diabetes mellitus.<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p><p>The Kidney Disease: Improving Global Outcomes clinical practice guideline for the care of kidney transplant recipients recommends pharmacokinetic monitoring of Tac to avoid under- or overexposure. Tac dose adjustments are usually made based on blood Tac trough concentrations (<italic toggle="yes">C</italic><sub>0</sub>) because it is the easiest approach, and Tac <italic toggle="yes">C</italic><sub>0</sub> is generally believed to correlate well with overall systemic exposure, as measured by the area-under-the-concentration-over-time curve (AUC).<sup><xref rid="R8" ref-type="bibr">8</xref>-<xref rid="R11" ref-type="bibr">11</xref></sup> The AUC measures the overall drug exposure and is considered the pharmacokinetic exposure parameter best associated with clinical outcomes.<sup><xref rid="R12" ref-type="bibr">12</xref>-<xref rid="R13" ref-type="bibr">13</xref></sup> However, there are conflicting reports on the correlation between <italic toggle="yes">C</italic><sub>0</sub> levels and the AUC.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> Some studies reported a reasonable squared correlation coefficient between trough levels and Tac AUC (0&#8722;12&#8201;h) (<italic toggle="yes">r</italic><sup>2</sup> = 0.60&#8211;0.85),<sup><xref rid="R15" ref-type="bibr">15</xref>-<xref rid="R17" ref-type="bibr">17</xref></sup> but others found poor correlations (<italic toggle="yes">r</italic><sup>2</sup> &lt; 0.50).<sup><xref rid="R18" ref-type="bibr">18</xref>-<xref rid="R19" ref-type="bibr">19</xref></sup> A retrospective study in &gt;500 patients on TacQD specifically found an <italic toggle="yes">r</italic><sup>2</sup> of 0.63, 0.66, and 0.75 in the first 3 mo, months 3 to 12, and beyond 1-y posttransplant, respectively.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></p><p>Our daily experience confirms that the Tac dose required to meet a specific target <italic toggle="yes">C</italic><sub>0</sub> varies highly among patients, with some individuals requiring up to 10-fold-higher doses than others.</p><p>The reports showing that trough levels may not be the ideal reflection of systemic exposure raised our concerns particularly regarding those requiring a high Tac dose to attain a therapeutic <italic toggle="yes">C</italic><sub>0</sub> level. Our hypothesis is that these patients may show an unexpectedly higher AUC at a therapeutic <italic toggle="yes">C</italic><sub>0</sub> level and may therefore be unintentionally overdosed.</p><p>The aim of the present study is to compare, retrospectively based on available data, the association between <italic toggle="yes">C</italic><sub>0</sub> and AUC in relation to Tac dose, with the hypothesis that patients requiring a high Tac dose for a certain <italic toggle="yes">C</italic><sub>0</sub> will also show higher AUC levels.</p><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Study Design/Participants</title><p>This is a single-center, retrospective study of adult kidney transplant recipients treated at the University Hospital of Antwerp (Belgium), for which a Tac AUC time curve from 0 to 24&#8201;h (Tac AUC<sub>24</sub>) was estimated between January 2019 and December 2021.</p><p>In some cases, Tac AUC<sub>24</sub>-monitoring was performed because of concerns about the relatively high Tac doses necessary to obtain an adequate <italic toggle="yes">C</italic><sub>0</sub>. In other cases, the Tac AUC<sub>24</sub> was measured in &#8220;random&#8221; patients who underwent mycophenolic acid AUC monitoring, which provided an opportunity to additionally analyze Tac levels, to obtain maximum insight into the patient&#8217;s immunosuppressant&#8217;s status. In the case that a patient underwent &gt;1 Tac AUC<sub>24</sub> analysis, only the earliest one was included in this study.</p><p>All patients were taking the TacQD formula (Advagraf). During 1&#8201;wk before the test, there were no modifications in administered Tac doses, nor in concomitant immunosuppressive therapy, to assure steady state. No patient received, during a week before the test, any strong interacting drug.<sup><xref rid="R21" ref-type="bibr">21</xref></sup></p><p>In general, the Tac dose was targeted to a <italic toggle="yes">C</italic><sub>0</sub> level of 8 to 10&#8201;ng/mL during the first month posttransplantation, to 6 to 8&#8201;ng/mL during the second and third months, and to 5 to 7&#8201;ng/mL thereafter. Concomitant immunosuppression generally comprised mycophenolate mofetil and corticosteroids, or occasionally a mammalian target of rapamycine inhibitor.</p></sec><sec><title>Pharmacokinetic Analysis</title><p>After the first blood sampling for trough concentration (<italic toggle="yes">C</italic><sub>0</sub>), approximately 24&#8201;h after the previous morning dose, the fasting patients took their usual TacQD dose together with their concomitant immunosuppressive medication. Then, blood samples were collected at 20&#8201;&#177;&#8201;15&#8201;min (T<sub>1</sub>), 60&#8201;&#177;&#8201;15&#8201;min (T<sub>2</sub>), 120&#8201;&#177;&#8201;15&#8201;min (T<sub>3</sub>), and 180&#8201;&#177;&#8201;30&#8201;min (T<sub>4</sub>), and the exact sampling times were recorded.</p><p>The <italic toggle="yes">C</italic><sub>0</sub>/<italic toggle="yes">D</italic> ratio was calculated by dividing the Tac <italic toggle="yes">C</italic><sub>0</sub> by the corresponding daily Tac dose (D).</p><p>Whole blood Tac concentrations were analyzed by liquid chromatography with tandem mass spectrometry using isotopically labeled standards on an XEVO TQMS instrument from Waters. Afterward, these data were sent to the laboratory of Pharmacology at the University Hospital of Limoges, where, based on the Immunosuppressant Bayesian Dose Adjustment system, an AUC<sub>24</sub> estimation was delivered. The Bayesian estimator used to determine Tac AUC<sub>24</sub> was developed at Limoges University Hospital on the basis of a 1-compartment open model with absorption described as a double gamma distribution, following a classic iterative 2-stage method, and applied to the 3-point limited sampling strategy predose and 1 and 3&#8201;h postdose.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> It was characterized by a mean bias of 4.2% &#177; 6.1% on day 14 and 0.2% &#177; 7.9% on day 42 posttransplant; the imprecision coefficients of variation were 7.1% and 7.8%, respectively.</p></sec><sec sec-type="subjects"><title>Classification of Patients</title><p>Patients were divided into a &#8220;low-dose&#8221; group with a Tac dose &#8804;0.15&#8201;mg/kg and an exposure &#8220;high-dose&#8221; group with a Tac dose &gt;0.15&#8201;mg/kg. This arbitrary cutoff level was determined before the analysis, based on clinical experience.</p></sec><sec><title>Statistical Analysis</title><p>Statistical analysis was performed using SPSS 28.0 (SPSS, Inc, Chicago, IL). Data with a normal distribution were presented as mean values with their SD.</p><p>Nominal data were presented by the number of patients and the percentage of total patients.</p><p>Categorical variables were compared between groups with the chi-square test; differences in continuous variables between groups were tested using the independent sample Student <italic toggle="yes">t</italic> test (parametric variables). All tests were 2-sided, and a <italic toggle="yes">P</italic> value below 0.05 was considered significant.</p><p>To assess whether the association between <italic toggle="yes">C</italic><sub>0</sub> and AUC<sub>24</sub> changes according to dose level, a multiple linear regression model was used with AUC<sub>24</sub> as the dependent variable and <italic toggle="yes">C</italic><sub>0</sub>, Tac dose, and interaction between both as independent variables. Tac dose is considered as both a continuous and a categorical variable (dose &lt;/&gt; 0.15 mg/kg). In a second stage, this model was adjusted for other influencing factors (age and race). Results were considered significant if <italic toggle="yes">P</italic> &lt; 0.05.</p><p>Pearson correlation coefficients between AUC<sub>24</sub> and <italic toggle="yes">C</italic><sub>0</sub> were calculated for each dose group (&lt;/&gt; 0.15 mg/kg) and compared using a <italic toggle="yes">t</italic> test on the Fisher transformed coefficients.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 53 patients were included in this study.</p><p>The baseline characteristics of the patients are listed in Table <xref rid="T1" ref-type="table">1</xref>. Thirty-six (68%) patients took a Tac dose &#8804;0.15&#8201;mg/kg, and 17 (32%) patients took a Tac dose &gt;0.15&#8201;mg/kg. The mean ages in the groups with low- and high-dose&#8211;treated recipients were 53.1&#8201;&#177;&#8201;13.0 y and 40.8&#8201;&#177;&#8201;13.5 y (mean &#177; SD), respectively (<italic toggle="yes">P</italic> &lt; 0.001). In the low-dose Tac group, 83% were of White race compared with 41% of the high-dose group (<italic toggle="yes">P</italic> &lt; 0.001). There was no significant difference in sex, body mass index, period after transplantation, and diabetes between patients in the low versus high Tac dose groups.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1.</label><caption><p>Demographic and clinical characteristics of patients (N = 53)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Low dose &#8804; 0.15&#8201;mg/kg (n = 36)</th><th align="center" rowspan="1" colspan="1">High dose &gt; 0.15&#8201;mg/kg (n = 17)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y<xref rid="T1Fn1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="center" rowspan="1" colspan="1">53.1&#8201;&#177;&#8201;13.0</td><td align="center" rowspan="1" colspan="1">40.8&#8201;&#177;&#8201;13.5</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Women, %</td><td align="center" rowspan="1" colspan="1">16 (44)</td><td align="center" rowspan="1" colspan="1">10 (59)</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> &#177; SD<xref rid="T1Fn1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="center" rowspan="1" colspan="1">27.2&#8201;&#177;&#8201;4.4</td><td align="center" rowspan="1" colspan="1">25.1&#8201;&#177;&#8201;3.8</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;White (%)</td><td align="center" rowspan="1" colspan="1">30 (83)</td><td align="center" rowspan="1" colspan="1">7 (41)</td><td align="center" rowspan="2" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other (%)</td><td align="center" rowspan="1" colspan="1">6 (17)</td><td align="center" rowspan="1" colspan="1">10 (59)</td></tr><tr><td align="left" rowspan="1" colspan="1">Days after transplantation (Q<sub>1</sub>; Q<sub>3</sub>)<xref rid="T1Fn2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="center" rowspan="1" colspan="1">106 (61; 835)</td><td align="center" rowspan="1" colspan="1">83 (54; 2094)</td><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes, %</td><td align="center" rowspan="1" colspan="1">11 (31)</td><td align="center" rowspan="1" colspan="1">4 (24)</td><td align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" colspan="4" rowspan="1">Concomitant immunosuppression</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Corticosteroids, %</td><td align="center" rowspan="1" colspan="1">30 (83)</td><td align="center" rowspan="1" colspan="1">16 (88)</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mycophenolate mofetil, %</td><td align="center" rowspan="1" colspan="1">31 (86)</td><td align="center" rowspan="1" colspan="1">14 (82)</td><td align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;mTOR, %</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1 (6)</td><td align="center" rowspan="1" colspan="1">0.58</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T1Fn1"><p><sup><italic toggle="yes">a</italic></sup>Values are expressed as mean &#177; SD.</p></fn><fn fn-type="other" id="T1Fn2"><p><sup><italic toggle="yes">b</italic></sup>Values are expressed as median and interquartile range (Q<sub>1</sub>; Q<sub>3</sub>).</p></fn><fn fn-type="other" id="T1Fn3"><p>BMI, body mass index; mTOR, mammalian target of rapamycine.</p></fn></table-wrap-foot></table-wrap><p>The pharmacokinetic parameters of Tac were compared between the 17 high-dose&#8211;treated recipients and 36 low-dose&#8211;treated recipients (Figure <xref rid="F1" ref-type="fig">1</xref>, Table <xref rid="T2" ref-type="table">2</xref>). In the low-dose subgroup, the mean daily Tac dose was 6.7&#8201;mg (&#177;2.1&#8201;mg), whereas in the high-dose&#8211;treated recipients, the mean daily dose was 17.4&#8201;mg (&#177;8.5&#8201;mg). Despite the large difference in daily Tac dose, the <italic toggle="yes">C</italic><sub>0</sub> level was not significantly different between the low-dose group (7.49&#8201;&#177;&#8201;2.47 &#181;g/L) and the high-dose group (7.24&#8201;&#177;&#8201;2.53 &#181;g/L; <italic toggle="yes">P</italic> = 0.74).</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2.</label><caption><p>Comparison of pharmacokinetic parameters between a Tac dose &#8804;0.15&#8201;mg/kg and a Tac dose &gt;0.15&#8201;mg/kg</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Low dose &#8804;0.15&#8201;mg/kg (n = 36)</th><th align="center" rowspan="1" colspan="1">High dose &gt;0.15&#8201;mg/kg (n = 17)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dose, mg</td><td align="center" rowspan="1" colspan="1">6.7&#8201;&#177;&#8201;2.1</td><td align="center" rowspan="1" colspan="1">17.4&#8201;&#177;&#8201;8.5</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose/body weight, mg/kg</td><td align="center" rowspan="1" colspan="1">0.09&#8201;&#177;&#8201;0.03</td><td align="center" rowspan="1" colspan="1">0.26&#8201;&#177;&#8201;0.13</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">C</italic><sub>0</sub>, &#956;g/L</td><td align="center" rowspan="1" colspan="1">7.49&#8201;&#177;&#8201;2.47</td><td align="center" rowspan="1" colspan="1">7.24&#8201;&#177;&#8201;2.53</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">C</italic><sub>max</sub>, &#956;g/L</td><td align="center" rowspan="1" colspan="1">21.36&#8201;&#177;&#8201;9.26</td><td align="center" rowspan="1" colspan="1">28.28&#8201;&#177;&#8201;9.85</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">C</italic><sub>0</sub> (ng/mL)/dose, mg)</td><td align="center" rowspan="1" colspan="1">1.21&#8201;&#177;&#8201;0.50</td><td align="center" rowspan="1" colspan="1">0.48&#8201;&#177;&#8201;0.23</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>24</sub> (h&#183;&#956;g/L)</td><td align="center" rowspan="1" colspan="1">255&#8201;&#177;&#8201;81</td><td align="center" rowspan="1" colspan="1">320&#8201;&#177;&#8201;96</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Concentration, &#956;g/L</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">C</italic><sub>1</sub></td><td align="center" rowspan="1" colspan="1">9.76&#8201;&#177;&#8201;4.43</td><td align="center" rowspan="1" colspan="1">10.64&#8201;&#177;&#8201;6.23</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">C</italic><sub>2</sub></td><td align="center" rowspan="1" colspan="1">18.02&#8201;&#177;&#8201;10.08</td><td align="center" rowspan="1" colspan="1">22.95&#8201;&#177;&#8201;10.38</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">C</italic><sub>3</sub></td><td align="center" rowspan="1" colspan="1">18.31&#8201;&#177;&#8201;8.68</td><td align="center" rowspan="1" colspan="1">22.95&#8201;&#177;&#8201;9.40</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">C</italic><sub>4</sub></td><td align="center" rowspan="1" colspan="1">16.13&#8201;&#177;&#8201;6.91</td><td align="center" rowspan="1" colspan="1">21.42&#8201;&#177;&#8201;7.63</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T2Fn1"><p>All values are expressed as mean &#177; SD. Concentration at &#177;20&#8201;min (<italic toggle="yes">C</italic><sub>1</sub>), &#177;60&#8201;min (<italic toggle="yes">C</italic><sub>2</sub>), &#177;120&#8201;min (<italic toggle="yes">C</italic><sub>3</sub>), and &#177;180&#8201;min (C<sub>4</sub>).</p></fn><fn fn-type="other" id="T2Fn2"><p>AUC<sub>24</sub>, area-under-the-concentration-over-time curve; <italic toggle="yes">C</italic><sub>max</sub>, maximal concentration; Tac, tacrolimus.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1.</label><caption><p>A blood-concentration time curve for a Tac dose &#8804;0.15&#8201;mg/kg and a Tac dose &gt;0.15&#8201;mg/kg (error bars represent SD of the mean). *Statistically significant. Tac, tacrolimus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="txd-9-e1439-g001.jpg"/></fig><p>The low-dose subgroup was linked with a higher <italic toggle="yes">C</italic><sub>0</sub>/<italic toggle="yes">D</italic> ratio than high-dose&#8211;treated recipients (1.21&#8201;&#177;&#8201;0.50&#8201;ng/mL/mg versus 0.48&#8201;&#177;&#8201;0.23&#8201;ng/mL/mg, respectively, <italic toggle="yes">P</italic> &lt; 0.001).</p><p>However, the mean AUC<sub>24</sub> was significantly higher in high-dose&#8211;treated recipients (320&#8201;&#177;&#8201;96 h&#183;&#956;g/L versus 255 &#177; 81 h&#183;&#956;g/L, <italic toggle="yes">P</italic> &lt; 0.001). The mean Tac <italic toggle="yes">C</italic><sub>max</sub> was also significantly higher in high-dose&#8211;treated recipients (28.28&#8201;&#177;&#8201;9.85 &#956;g/L versus 21.36&#8201;&#177;&#8201;9.26 &#956;g/L, <italic toggle="yes">P</italic> &lt; 0.001).</p><p>The correlation between <italic toggle="yes">C</italic><sub>0</sub> concentration and AUC<sub>24</sub> was higher in the low-dose&#8211;treated patients than in the high-dose&#8211;treated patients (respectively, <italic toggle="yes">r</italic><sup>2</sup> = 0.91 versus 0.77). This difference was not statistically significant (<italic toggle="yes">P</italic> = 0.14).</p><p>Association between <italic toggle="yes">C</italic><sub>0</sub> concentration and AUC<sub>24</sub> was further examined and compared between low-dose&#8211;treated recipients and high-dose&#8211;treated recipients in a linear regression model. This confirms that, in high-dose&#8211;treated recipients, the AUC<sub>24</sub> is 72 h&#183;&#956;g/L higher than in patients treated with low-dose Tac (<italic toggle="yes">P</italic> &lt; 0.001; Table <xref rid="T3" ref-type="table">3</xref>), a difference that also remained significant after adjusting for age and race. Additional exploration, using a model that incorporated a term for interaction between dose-group and <italic toggle="yes">C</italic><sub>0</sub>, shows no significant difference in the relationship between <italic toggle="yes">C</italic><sub>0</sub> and the AUC<sub>24</sub> in both groups (<italic toggle="yes">P</italic> = 0.9), meaning that the way in which the AUC<sub>24</sub> increases with higher <italic toggle="yes">C</italic><sub>0</sub> levels is similar in patients taking a low versus high dose of Tac (but the high dose group starts at a higher intercept; Figure <xref rid="F2" ref-type="fig">2</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3.</label><caption><p>Factors that influence the relationship between the <italic toggle="yes">C</italic><sub>0</sub> and AUC in a linear regression model with AUC as outcome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Not adjusted</th><th align="center" colspan="2" rowspan="1">Adjusted<xref rid="T3Fn1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th></tr><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">B</italic> coefficient (SE)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">B</italic> coefficient (SE)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Constant</td><td align="center" rowspan="1" colspan="1">105.96 (21.27)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">91.39 (27.64)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">C</italic><sub>0</sub> (&#956;g/L)</td><td align="center" rowspan="1" colspan="1">29.51 (2.52)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">29.09 (2.51)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Tac dose &gt; 0.15&#8201;mg/kg<xref rid="T3Fn2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="center" rowspan="1" colspan="1">72 (13)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">66 (14)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.84 (0.49)</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Race: non-White<xref rid="T3Fn3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">38.51 (15.34)</td><td align="center" rowspan="1" colspan="1">0.10</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T3Fn1"><p><sup><italic toggle="yes">a</italic></sup>After adjusting for age and race.</p></fn><fn fn-type="other" id="T3Fn2"><p><sup><italic toggle="yes">b</italic></sup>Reference category Tac dose &#8804; 0.15&#8201;mg/kg.</p></fn><fn fn-type="other" id="T3Fn3"><p><sup><italic toggle="yes">c</italic></sup>Reference category White.</p></fn><fn fn-type="other" id="T3Fn4"><p>AUC, area-under-the-concentration-over-time curve; Tac, tacrolimus</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2.</label><caption><p>Scatterplot graph showing the association between the <italic toggle="yes">C</italic><sub>0</sub> and AUC<sub>24</sub> in 36 patients with a low dose of Tac (&#9661;) and in 17 patients with a high dose of Tac (&#8226;). The dotted line indicates the regression equation. AUC, area-under-the-concentration-over-time curve; Tac, tacrolimus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="txd-9-e1439-g002.jpg"/></fig><p>When looking at Tac dose as a continuous variable instead of 2 categories (low/high), the conclusion remains that, for the same <italic toggle="yes">C</italic><sub>0</sub>, a higher Tac dose results in a higher AUC<sub>24</sub>: For every 0.01&#8201;mg/kg increase in the dose of Tac, the AUC<sub>24</sub> increases by 3.59 h&#183;&#956;g/L.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our study confirms the hypothesis that patients requiring a high Tac dose (&gt;0.15&#8201;mg/kg) to achieve a therapeutic target Tac <italic toggle="yes">C</italic><sub>0</sub> level show a significantly higher AUC<sub>24</sub> than patients requiring a low Tac dose. In other words, we risk to overdose those patients if we only target their Tac dose to the <italic toggle="yes">C</italic><sub>0</sub> level.</p><p>Despite similar <italic toggle="yes">C</italic><sub>0</sub> levels, we found that the AUC<sub>24</sub> was about 25% (72 h&#183;&#956;g/L) higher in patients taking a high Tac dose than in patients on a low Tac dose. An increase in a Tac dose of 0.01&#8201;mg/kg results in an AUC<sub>24</sub> increase by 3.59 h&#183;&#956;g/L.</p><p>The AUC is the most accurate measure of overall drug exposure and is considered the pharmacokinetic exposure parameter best associated with clinical outcomes.<sup><xref rid="R12" ref-type="bibr">12</xref>-<xref rid="R13" ref-type="bibr">13</xref></sup> However, most centers still rely on <italic toggle="yes">C</italic><sub>0</sub>-level monitoring, despite conflicting data about the correlation with systemic exposure.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> We report here a better correlation coefficient between <italic toggle="yes">C</italic><sub>0</sub> and AUC<sub>24</sub> in the low-dose&#8211;treated patients than in the high-dose&#8211;treated patients (respectively, <italic toggle="yes">r</italic><sup>2</sup> = 0.91 versus 0.77), which indicates that <italic toggle="yes">C</italic><sub>0</sub> level is a less reliable tool to estimate systemic exposure in patients requiring a high Tac dose.</p><p>However, only a few studies have investigated the relationship between Tac systemic exposure and the risk of toxicity.<sup><xref rid="R22" ref-type="bibr">22</xref>-<xref rid="R23" ref-type="bibr">23</xref></sup> The conclusion from these studies was that Tac monitoring may be useful for minimizing the risks of both toxicity and rejection in kidney transplant recipients.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> The increased risk for Tac-treated patients to develop nephrotoxicity, neurotoxicity, and posttransplant diabetes mellitus may theoretically be reduced by AUC monitoring, although, until now, no prospective trials<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> have been published that evaluated the potential benefits on clinical outcomes of AUC monitoring compared with <italic toggle="yes">C</italic><sub>0</sub>-guided therapy on these side effects.<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p><p>Recently, the trough concentration/dose (<italic toggle="yes">C</italic><sub>0</sub>/D) ratio of Tac has been proposed as a prognostic marker for poor outcome after kidney transplantation.<sup><xref rid="R25" ref-type="bibr">25</xref>-<xref rid="R26" ref-type="bibr">26</xref></sup> Patients with a low <italic toggle="yes">C</italic><sub>0</sub>/<italic toggle="yes">D</italic> ratio (&lt;1.05&#8201;ng/mL/mg, also referred to as fast metabolizers) seem to have more Tac-related nephrotoxicity, more BK viremia, and a shorter graft survival. We confirmed that high-dose&#8211;treated recipients showed a <italic toggle="yes">C</italic><sub>0</sub>/<italic toggle="yes">D</italic> ratio &lt;1.05&#8201;ng/mL/mg (0.48&#8201;ng/mL/mg), thus identifying a group of patients with potentially increased risk of poor outcome.</p><p>Our data suggest that a Tac AUC estimation might have an added value in patients requiring a high Tac dose for an adequate <italic toggle="yes">C</italic><sub>0</sub>. Although it is more laborious and costly, it might be worth the effort in this subgroup. However, it may not be feasible to repeat AUC testing at every standard follow-up visit. More research is needed to define the frequency or specific circumstances in which to repeat this. Of note, implementation of home-based dried blood spot Tac sampling could promote regular AUC monitoring. Alternatively, it might be interesting to continue the follow-up by using <italic toggle="yes">C</italic><sub>0</sub> levels but to adapt the target <italic toggle="yes">C</italic><sub>0</sub> according to the AUC (eg, if you targeted a Tac <italic toggle="yes">C</italic><sub>0</sub> of 7 &#181;g/mL but the AUC was too high, then to target a lower <italic toggle="yes">C</italic><sub>0</sub>). Reassuring, in this respect, is that a large, retrospective study showed no significant changes in the AUC/<italic toggle="yes">C</italic><sub>0</sub> ratio over posttransplantation time (before versus after 6 mo), suggesting that, indeed, it could be used to infer an individual <italic toggle="yes">C</italic><sub>0</sub> target to achieve a target AUC.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Ideally, future prospective studies should compare AUC-guided dosing versus standard <italic toggle="yes">C</italic><sub>0</sub> monitoring to determine the impact on the prevention of acute rejection episodes, nephrotoxicity, and other known adverse reactions.</p><p>To our knowledge, our study is the first to specifically investigate the impact of a high Tac dose on the relationship between <italic toggle="yes">C</italic><sub>0</sub> and AUC. Despite the modest sample size, we were able to demonstrate a statistically significant and clinically relevant increase of the total Tac exposure (AUC<sub>24</sub>) despite similar <italic toggle="yes">C</italic><sub>0</sub> values in such patients. However, AUC<sub>24</sub> estimates were obtained using an LSS in combination with Bayesian estimation based on a pharmacokinetic model, which despite low inaccuracy (&lt;5%) and imprecision (&lt;8%) following the authors<sup><xref rid="R27" ref-type="bibr">27</xref></sup> can be affected by different sources of errors, such as in the sampling times and measured plasma levels, similar to <italic toggle="yes">C</italic><sub>0</sub> in this respect. On the other hand, Immunosuppressant Bayesian Dose Adjustment is an expert system routinely used by 140 transplantation centers around the world for the dose adjustment of immunosuppressive drugs in transplant patients.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Another strength of this study is that it combined detailed data on Tac pharmacokinetics with clinical patient information so that we could avoid that our findings were confounded by age, by the concomitant use of strongly interacting drugs, and, to some extent, by race. Regarding the latter, it is indeed known that CYP3A4 and CYP3A5 gene polymorphisms can explain some of the interpatient variability in Tac pharmacokinetics and that these genotypes vary by race (eg, more rapid metabolizers in African American and Asian populations).<sup><xref rid="R29" ref-type="bibr">29</xref>-<xref rid="R30" ref-type="bibr">30</xref></sup> Given the highly heterogeneous racial background of our small non-White subgroup and the lack of genotyping, we were unfortunately unable to perform an in-depth analysis of the role of genetic variations on the relationship between Tac dose, <italic toggle="yes">C</italic><sub>0</sub>, and AUC. Another limitation is the lack of information about the clinical outcome of the recipients. It would be interesting to evaluate potential benefits on clinical outcomes of AUC monitoring compared with <italic toggle="yes">C</italic><sub>0</sub>-level therapy.</p></sec><sec><title>CONCLUSION</title><p>The findings of this study challenge the general belief that <italic toggle="yes">C</italic><sub>0</sub> levels are sufficiently reliable to estimate the total Tac exposure. We demonstrated that patients requiring a relatively high Tac dose (&#8805;0.15&#8201;mg/dL) to achieve therapeutic <italic toggle="yes">C</italic><sub>0</sub> levels have a higher total drug exposure and could therefore potentially be overdosed. This study shows that performing a Tac AUC measurement may be worth the effort in such patients, but this does not exclude that it could be valuable for low-dose patients, too, particularly to control low exposure more precisely.</p></sec><sec><title>ACKNOWLEDGMENTS</title><p>We would like to thank all patients who participated and are thankful for the great technical assistance from Limoges University Hospital in the process of capturing data. We would like to acknowledge Kristien Wouters, statistician, whose statistical expertise was invaluable during the analysis and interpretation of the data that have been collected. We thank Erik Snelders for the excellent administrative support.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>The authors declare no funding or conflicts of interest.</p></fn><fn fn-type="equal"><p>L.H., R.H., L.R., A.M., and D.A. contributed to the design of the study. K.W. performed the statistical analyses. L.H. and R.H. wrote the first draft of the manuscript. P.M. and C.M. reviewed and edited the manuscript and contributed to the critical revision of the manuscript for important intellectual content. All authors contributed to data acquisition, the analysis or interpretation of results, and critical revision of the article for intellectually important content. L.H., D.A., and R.H. contributed to the concept and design.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Tedesco-Silva</surname><given-names>H</given-names></name><name name-style="western"><surname>Demirbas</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Reduced exposure to calcineurin inhibitors in renal transplantation.</article-title><source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>:<fpage>2562</fpage>&#8211;<lpage>2575</lpage>.<pub-id pub-id-type="pmid">18094377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa067411</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caillard</surname><given-names>S</given-names></name><name name-style="western"><surname>Moulin</surname><given-names>B</given-names></name><name name-style="western"><surname>Buron</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Advagraf, a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts.</article-title><source>Transpl Int</source>. <year>2016</year>;<volume>29</volume>:<fpage>860</fpage>&#8211;<lpage>869</lpage>.<pub-id pub-id-type="pmid">26373896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tri.12674</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albano</surname><given-names>L</given-names></name><name name-style="western"><surname>Banas</surname><given-names>B</given-names></name><name name-style="western"><surname>Klempnauer</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation.</article-title><source>Transplantation</source>. <year>2013</year>;<volume>96</volume>:<fpage>897</fpage>&#8211;<lpage>903</lpage>.<pub-id pub-id-type="pmid">23982340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0b013e3182a203bd</pub-id><pub-id pub-id-type="pmcid">PMC3864174</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuteja</surname><given-names>S</given-names></name><name name-style="western"><surname>Alloway</surname><given-names>RR</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients.</article-title><source>Transplantation</source>. <year>2001</year>;<volume>71</volume>:<fpage>1303</fpage>&#8211;<lpage>1307</lpage>.<pub-id pub-id-type="pmid">11397967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-200105150-00021</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholten</surname><given-names>EM</given-names></name><name name-style="western"><surname>Cremers</surname><given-names>SC</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>RC</given-names></name><etal/></person-group>. <article-title>AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients.</article-title><source>Kidney Int</source>. <year>2005</year>;<volume>67</volume>:<fpage>2440</fpage>&#8211;<lpage>2447</lpage>.<pub-id pub-id-type="pmid">15882290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1523-1755.2005.00352.x</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seibert</surname><given-names>SR</given-names></name><name name-style="western"><surname>Schladt</surname><given-names>DP</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: effects on acute rejection and graft failure in European American and African American kidney transplant recipients.</article-title><source>Clin Transplant</source>. <year>2018</year>;<volume>32</volume>:<fpage>e13424</fpage>.<pub-id pub-id-type="pmid">30318646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ctr.13424</pub-id><pub-id pub-id-type="pmcid">PMC6317347</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiff</surname><given-names>J</given-names></name><name name-style="western"><surname>Cole</surname><given-names>E</given-names></name><name name-style="western"><surname>Cantarovich</surname><given-names>M</given-names></name></person-group>. <article-title>Therapeutic monitoring of calcineurin inhibitors for the nephrologist.</article-title><source>Clin J Am Soc Nephrol</source>. <year>2007</year>;<volume>2</volume>:<fpage>374</fpage>&#8211;<lpage>384</lpage>.<pub-id pub-id-type="pmid">17699437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.03791106</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallemacq</surname><given-names>P</given-names></name><name name-style="western"><surname>Goffinet</surname><given-names>J</given-names></name><name name-style="western"><surname>O&#8217;Morchoe</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay.</article-title><source>Ther Drug Monit</source>. <year>2009</year>;<volume>31</volume>:<fpage>198139</fpage>&#8211;<lpage>198204</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0b013e31819c6a37</pub-id><pub-id pub-id-type="pmid">19258928</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaj</surname><given-names>J</given-names></name><name name-style="western"><surname>Johan</surname><given-names>P</given-names></name><name name-style="western"><surname>S&#248;ren</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients.</article-title><source>Nephrol Dial Transplant</source>. <year>2002</year>;<volume>17</volume>:<fpage>1487</fpage>&#8211;<lpage>1490</lpage>.<pub-id pub-id-type="pmid">12147799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/17.8.1487</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><article-title>Group TKDIGOW. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.</article-title><source>Transplantation</source><year>2020</year>;<volume>104</volume>:<fpage>S11</fpage>&#8211;<lpage>S103</lpage>.<pub-id pub-id-type="pmid">32301874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0000000000003136</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woillard</surname><given-names>JB</given-names></name><name name-style="western"><surname>Saint-Marcoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Debord</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose.</article-title><source>Pharmacol Res</source>. <year>2018</year>;<volume>130</volume>:<fpage>316</fpage>&#8211;<lpage>321</lpage>.<pub-id pub-id-type="pmid">29452291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2018.02.016</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunet</surname><given-names>M</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name><name name-style="western"><surname>&#197;sberg</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report.</article-title><source>Ther Drug Monit</source>. <year>2019</year>;<volume>41</volume>:<fpage>261</fpage>&#8211;<lpage>307</lpage>.<pub-id pub-id-type="pmid">31045868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0000000000000640</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallemacq</surname><given-names>P</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>VW</given-names></name><name name-style="western"><surname>Brunet</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.</article-title><source>Ther Drug Monit</source>. <year>2009</year>;<volume>31</volume>:<fpage>139</fpage>&#8211;<lpage>152</lpage>.<pub-id pub-id-type="pmid">19177031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0b013e318198d092</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saint-Marcoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Woillard</surname><given-names>JB</given-names></name><name name-style="western"><surname>Jurado</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure.</article-title><source>Ther Drug Monit</source>. <year>2013</year>;<volume>35</volume>:<fpage>322</fpage>&#8211;<lpage>327</lpage>.<pub-id pub-id-type="pmid">23666572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0b013e318285e779</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>F</given-names></name><name name-style="western"><surname>Sch&#252;tz</surname><given-names>E</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients.</article-title><source>Transplant Proc</source>. <year>2001</year>;<volume>33</volume>:<fpage>2127</fpage>&#8211;<lpage>2128</lpage>.<pub-id pub-id-type="pmid">11377473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0041-1345(01)01970-4</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimikawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamoya</surname><given-names>K</given-names></name><name name-style="western"><surname>Toma</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Effective oral administration of tacrolimus in renal transplant recipients.</article-title><source>Clin Transplant</source>. <year>2001</year>;<volume>15</volume>:<fpage>324</fpage>&#8211;<lpage>329</lpage>.<pub-id pub-id-type="pmid">11678958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1399-0012.2001.150504.x</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardinger</surname><given-names>KL</given-names></name><name name-style="western"><surname>Park</surname><given-names>JM</given-names></name><name name-style="western"><surname>Schnitzler</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing.</article-title><source>Am J Transplant</source>. <year>2004</year>;<volume>4</volume>:<fpage>621</fpage>&#8211;<lpage>625</lpage>.<pub-id pub-id-type="pmid">15023155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-6143.2004.00383.x</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>KM</given-names></name><name name-style="western"><surname>Shek</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chau</surname><given-names>KF</given-names></name><etal/></person-group>. <article-title>Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients.</article-title><source>Am J Kidney Dis</source>. <year>2000</year>;<volume>35</volume>:<fpage>660</fpage>&#8211;<lpage>666</lpage>.<pub-id pub-id-type="pmid">10739787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(00)70013-8</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tada</surname><given-names>H</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>S</given-names></name><name name-style="western"><surname>Iinuma</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection.</article-title><source>J Clin Pharmacol</source>. <year>2003</year>;<volume>43</volume>:<fpage>859</fpage>&#8211;<lpage>865</lpage>.<pub-id pub-id-type="pmid">12953343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270003254797</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquet</surname><given-names>P</given-names></name><name name-style="western"><surname>Bedu</surname><given-names>A</given-names></name><name name-style="western"><surname>Monchaud</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Pharmacokinetic therapeutic drug monitoring of Advagraf in more than 500 adult renal transplant patients, using an expert system online.</article-title><source>Ther Drug Monit</source>. <year>2018</year>;<volume>40</volume>:<fpage>285</fpage>&#8211;<lpage>291</lpage>.<pub-id pub-id-type="pmid">29505493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0000000000000503</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name></person-group>. <article-title>Drug interactions with tacrolimus.</article-title><source>Drug Saf</source>. <year>2002</year>;<volume>25</volume>:<fpage>707</fpage>&#8211;<lpage>712</lpage>.<pub-id pub-id-type="pmid">12167066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00002018-200225100-00003</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kershner</surname><given-names>RP</given-names></name><name name-style="western"><surname>Fitzsimmons</surname><given-names>WE</given-names></name></person-group>. <article-title>Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation.</article-title><source>Transplantation</source>. <year>1996</year>;<volume>62</volume>:<fpage>920</fpage>&#8211;<lpage>926</lpage>.<pub-id pub-id-type="pmid">8878385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199610150-00009</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#246;ttiger</surname><given-names>Y</given-names></name><name name-style="western"><surname>Brattstr&#246;m</surname><given-names>C</given-names></name><name name-style="western"><surname>Tyd&#233;n</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients.</article-title><source>Br J Clin Pharmacol</source>. <year>1999</year>;<volume>48</volume>:<fpage>445</fpage>&#8211;<lpage>448</lpage>.<pub-id pub-id-type="pmid">10510159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.1999.00007.x</pub-id><pub-id pub-id-type="pmcid">PMC2014338</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchida</surname><given-names>K</given-names></name><name name-style="western"><surname>Tominaga</surname><given-names>Y</given-names></name><name name-style="western"><surname>Haba</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation.</article-title><source>Transplant Proc</source>. <year>2002</year>;<volume>34</volume>:<fpage>1736</fpage>&#8211;<lpage>1737</lpage>.<pub-id pub-id-type="pmid">12176556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0041-1345(02)03002-6</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name><name name-style="western"><surname>Meziyerh</surname><given-names>S</given-names></name><name name-style="western"><surname>Swen</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>The clinical impact of the C0/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients.</article-title><source>Front Pharmacol</source>. <year>2020</year>;<volume>11</volume>:<fpage>1142</fpage>.<pub-id pub-id-type="pmid">32848756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.01142</pub-id><pub-id pub-id-type="pmcid">PMC7411304</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Th&#246;lking</surname><given-names>G</given-names></name><name name-style="western"><surname>Sch&#252;tte-N&#252;tgen</surname><given-names>K</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>A low tacrolimus concentration/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity.</article-title><source>J Clin Med</source>. <year>2019</year>;<volume>8</volume>:<fpage>1586</fpage>.<pub-id pub-id-type="pmid">31581670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm8101586</pub-id><pub-id pub-id-type="pmcid">PMC6832469</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saint-Marcoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Debord</surname><given-names>J</given-names></name><name name-style="western"><surname>Nasrullah</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.</article-title><source>Ther Drug Monit</source>. <year>2010</year>;<volume>32</volume>:<fpage>129</fpage>&#8211;<lpage>135</lpage>.<pub-id pub-id-type="pmid">20110850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0b013e3181cc70db</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benkali</surname><given-names>K</given-names></name><name name-style="western"><surname>Rostaing</surname><given-names>L</given-names></name><name name-style="western"><surname>Premaud</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.</article-title><source>Clin Pharmacokinet</source>. <year>2010</year>;<volume>49</volume>:<fpage>683</fpage>&#8211;<lpage>692</lpage>.<pub-id pub-id-type="pmid">20818834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11535950-000000000-00000</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanghavi</surname><given-names>K</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>RC</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.</article-title><source>Pharmacogenomics J</source>. <year>2017</year>;<volume>17</volume>:<fpage>61</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">26667830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tpj.2015.87</pub-id><pub-id pub-id-type="pmcid">PMC4909584</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taber</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Gebregziabher</surname><given-names>MG</given-names></name><name name-style="western"><surname>Srinivas</surname><given-names>TR</given-names></name><etal/></person-group>. <article-title>African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients.</article-title><source>Pharmacotherapy</source>. <year>2015</year>;<volume>35</volume>:<fpage>569</fpage>&#8211;<lpage>577</lpage>.<pub-id pub-id-type="pmid">26011276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.1591</pub-id><pub-id pub-id-type="pmcid">PMC4534305</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>